Stockscreener 앱 받기
12.02
0.66%
-0.08
시간 외 거래:
11.80
-0.22
-1.83%
전일 마감가:
$12.10
열려 있는:
$12.11
하루 거래량:
1.71M
Relative Volume:
1.05
시가총액:
$1.24B
수익:
-
순이익/손실:
$-135.21M
주가수익비율:
-8.3991
EPS:
-1.4311
순현금흐름:
$-114.35M
1주 성능:
+15.36%
1개월 성능:
+26.13%
6개월 성능:
-0.74%
1년 성능:
+5.07%
1일 변동 폭
$11.92
$12.57
1주일 범위
$10.37
$12.57
52주 변동 폭
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.02 | 1.25B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-12 | 재개 | Stifel | Buy |
| 2026-05-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Oric Pharmaceuticals Inc (ORIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oric Pharmaceuticals Inc (ORIC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Orbimed Advisors LLC Reduces Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
ORIC|Oric Pharmaceuticals Inc|Price:12.100|Chg%:+1.210 - TradingKey
Oric Pharmaceuticals Inc (ORIC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Oric Pharmaceuticals Inc (ORIC) Institutional Confidence - TradingKey
Oric Pharmaceuticals Inc (ORIC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oric Pharmaceuticals Inc (ORIC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 5.4%Time to Buy? - MarketBeat
Siren L.L.C. Has $37.99 Million Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (ORIC) Stock Analysis: A Biotech Gem With An 86% Upside Potential - DirectorsTalk Interviews
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen Bull Case (NASDAQ:ORIC) - Seeking Alpha
Oric Pharmaceuticals stock trades down to 10.69 as oricpharma promotes BTIG conference meeting - Traders Union
Discipline and Rules-Based Execution in ORIC Response - Stock Traders Daily
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - The Manila Times
ORIC® Pharmaceuticals Announces Three Presentations at the - GlobeNewswire
Oric Pharmaceuticals (ORIC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC) - Sahm
ORIC Launches Phase 3 Himalayas-1 Trial - t.co
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Sahm
Oric Pharmaceuticals (ORIC) Launches Phase 3 Trial for Prostate Cancer Treatment - GuruFocus
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial - Investing.com
ORIC Pharmaceuticals initiates phase 3 prostate cancer trial By Investing.com - Investing.com India
Bayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial - Stock Titan
Y Intercept Hong Kong Ltd Sells 229,431 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals director Heyman sells $3,600 in stock - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Oric Pharmaceuticals director Heyman sells $3,600 in stock By Investing.com - Investing.com India
Oric Pharmaceuticals (ORIC) entity sells 300 shares under 10b5-1 plan - Stock Titan
Price to sales forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC focuses on oncology pipeline as Oric Pharmaceuticals positions for long-term growth - Ad Hoc News
Price to sales forward of Oric Pharmaceuticals, Inc. – DUS:4TZ - TradingView
Form 144 Oric Pharmaceuticals For: 6 July By Investing.com - Investing.com Nigeria
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals Slips 2.49% as Stock Tests Key Support LevelsBreakout Stock Alerts - DonanımHaber
Oric Pharmaceuticals stock extends rally with bullish signals after 22 percent weekly surge - Traders Union
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC awards new hires 44,400 stock options and 7,200 RSUs - Stock Titan
ORIC Pharmaceuticals grants stock options and r... - Pluang
Wedbush reiterates ORIC Pharmaceuticals (ORIC) outperform recommendation - MSN
Enterprise value to EBITDA forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Price to earnings forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Price to book forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – FWB:4TZ - TradingView
Enterprise value to EBIT forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):